Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with ...

Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma.

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

NSAID use is associated with an increased risk of death from RCC among women but not among men, researchers found.

A personalized vaccine against advanced kidney cancer has shown encouraging results in a clinical trial, with all nine ...